| MEIS2 suppresses breast cancer development by downregulating IL10. | MEIS2 suppresses breast cancer development by downregulating IL10.
Xiao Y, Liu Y, Sun Y, Huang C, Zhong S., Free PMC Article | 05/23/2024 |
| Novel genetic markers for chronic kidney disease in a geographically isolated population of Indigenous Australians: Individual and multiple phenotype genome-wide association study. | Novel genetic markers for chronic kidney disease in a geographically isolated population of Indigenous Australians: Individual and multiple phenotype genome-wide association study.
Arunachalam V, Lea R, Hoy W, Lee S, Mott S, Savige J, Mathews JD, McMorran BJ, Nagaraj SH., Free PMC Article | 03/4/2024 |
| Cellular Ligand-Receptor Perturbations Unravel MEIS2 as a Key Factor for the Aggressive Progression and Prognosis in Stage II/III Colorectal Cancer. | Cellular Ligand-Receptor Perturbations Unravel MEIS2 as a Key Factor for the Aggressive Progression and Prognosis in Stage II/III Colorectal Cancer.
Xu H, Chen S, Li J, Weng S, Ren Y, Zhang Y, Wang L, Liu L, Guo C, Xing Z, Luo P, Cheng Q, Han X, Liu Z. | 02/12/2024 |
| LINC-PINT suppresses breast cancer cell proliferation and migration via MEIS2/PPP3CC/NF-kappaB pathway by sponging miR-576-5p. | LINC-PINT suppresses breast cancer cell proliferation and migration via MEIS2/PPP3CC/NF-κB pathway by sponging miR-576-5p.
Li D, Hu A. | 02/9/2024 |
| IGF2BP2 promotes the progression of ovarian endometriosis by regulating m6A-modified MEIS2 and GATA6. | IGF2BP2 promotes the progression of ovarian endometriosis by regulating m6A-modified MEIS2 and GATA6.
Zhao S, Zhang B, Yuan H, Yin Y, Qi S, Li W, Wu X, Yaling F. | 11/13/2023 |
| CircDHRS3 inhibits prostate cancer cell proliferation and metastasis through the circDHRS3/miR-421/MEIS2 axis. | CircDHRS3 inhibits prostate cancer cell proliferation and metastasis through the circDHRS3/miR-421/MEIS2 axis.
Dai X, Chen X, Chen W, Ou Y, Chen Y, Wu S, Zhou Q, Yang C, Zhang L, Jiang H., Free PMC Article | 02/28/2023 |
| Meis homeobox 2 (MEIS2) inhibits the proliferation and promotes apoptosis of thyroid cancer cell and through the NF-kappaB signaling pathway. | Meis homeobox 2 (MEIS2) inhibits the proliferation and promotes apoptosis of thyroid cancer cell and through the NF-κB signaling pathway.
Wen X, Liu M, Du J, Wang X., Free PMC Article | 11/13/2021 |
| Intellectual disability associated with craniofacial dysmorphism, cleft palate, and congenital heart defect due to a de novo MEIS2 mutation: A clinical longitudinal study. | Intellectual disability associated with craniofacial dysmorphism, cleft palate, and congenital heart defect due to a de novo MEIS2 mutation: A clinical longitudinal study.
Gangfuß A, Yigit G, Altmüller J, Nürnberg P, Czeschik JC, Wollnik B, Bögershausen N, Burfeind P, Wieczorek D, Kaiser F, Roos A, Kölbel H, Schara-Schmidt U, Kuechler A. | 08/7/2021 |
| Expression of ISL1 and its partners in prostate cancer progression and neuroendocrine differentiation. | Expression of ISL1 and its partners in prostate cancer progression and neuroendocrine differentiation.
Alshalalfa M, Abou-Ouf H, Davicioni E, Karnes RJ, Alhajj R, Bismar TA. | 07/10/2021 |
| MEIS2 sequence variant in a child with intellectual disability and cardiac defects: Expansion of the phenotypic spectrum and documentation of low-level mosaicism in an unaffected parent. | MEIS2 sequence variant in a child with intellectual disability and cardiac defects: Expansion of the phenotypic spectrum and documentation of low-level mosaicism in an unaffected parent.
Su JX, Velsher LS, Juusola J, Nezarati MM. | 07/3/2021 |
| Inhibition of Senescence-Associated Genes Rb1 and Meis2 in Adult Cardiomyocytes Results in Cell Cycle Reentry and Cardiac Repair Post-Myocardial Infarction. | Inhibition of Senescence-Associated Genes Rb1 and Meis2 in Adult Cardiomyocytes Results in Cell Cycle Reentry and Cardiac Repair Post-Myocardial Infarction.
Alam P, Haile B, Arif M, Pandey R, Rokvic M, Nieman M, Maliken BD, Paul A, Wang YG, Sadayappan S, Ahmed RPH, Kanisicak O., Free PMC Article | 01/9/2021 |
| Results strongly indicate that aberrant DNA hypermethylation is associated with epigenetic silencing of MEIS2 transcriptional expression in prostate cancer (PC) and validate MEIS2 as a potential prognostic biomarker for PC. | Epigenetic silencing of MEIS2 in prostate cancer recurrence.
Nørgaard M, Haldrup C, Bjerre MT, Høyer S, Ulhøi B, Borre M, Sørensen KD., Free PMC Article | 08/1/2020 |
| MEIS2 might be involved in the Wnt/beta-catenin pathway. | Hypermethylated and downregulated MEIS2 are involved in stemness properties and oxaliplatin-based chemotherapy resistance of colorectal cancer.
Wang X, Ghareeb WM, Zhang Y, Yu Q, Lu X, Huang Y, Huang S, Sun Y, Chi P. | 05/30/2020 |
| MEISC/D promote hepatocellular carcinoma development via Wnt/beta-catenin and Hippo/YAP signaling pathways | MEIS2C and MEIS2D promote tumor progression via Wnt/β-catenin and hippo/YAP signaling in hepatocellular carcinoma.
Guan L, Li T, Ai N, Wang W, He B, Bai Y, Yu Z, Li M, Dong S, Zhu Q, Ding XX, Zhang S, Li M, Tang G, Xia X, Zhao J, Lin S, Yao S, Zhang L, Chen G, Liu FE, Li X, Zhang H., Free PMC Article | 02/22/2020 |
| Study shows that MEIS2 expression is regulated in bladder neoplasm via alternative splicing by PTBP1. | Polypyrimidine tract binding protein 1 promotes lymphatic metastasis and proliferation of bladder cancer via alternative splicing of MEIS2 and PKM.
Xie R, Chen X, Chen Z, Huang M, Dong W, Gu P, Zhang J, Zhou Q, Dong W, Han J, Wang X, Li H, Huang J, Lin T. | 01/25/2020 |
| Study demonstrated that MEIS2 acted as a promoter of metastasis in colorectal cancer (CRC). Knockdown of MEIS2 significantly suppressed CRC migration, invasion and EMT. MEIS2 was associated with a shorter overall survival time for patients with CRC. These results suggest that MEIS2 may serve as a novel biomarker for CRC. | MEIS2 promotes cell migration and invasion in colorectal cancer.
Wan Z, Chai R, Yuan H, Chen B, Dong Q, Zheng B, Mou X, Pan W, Tu Y, Yang Q, Tu S, Hu X., Free PMC Article | 12/28/2019 |
| These data implicate a functional role for MEIS proteins in regulating cancer progression, and support a hypothesis whereby tumor expression of MEIS1 and MEIS2 expression confers a more indolent prostate cancer phenotype, with a decreased propensity for metastatic progression | MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease.
Bhanvadia RR, VanOpstall C, Brechka H, Barashi NS, Gillard M, McAuley EM, Vasquez JM, Paner G, Chan WC, Andrade J, De Marzo AM, Han M, Szmulewitz RZ, Vander Griend DJ., Free PMC Article | 12/21/2019 |
| The present study indicated that Meis2 repress the osteoblastic transdifferentiation of aortic valve interstitial cells through the Notch1/Twist1 signaling pathway. | Meis2 represses the osteoblastic transdifferentiation of aortic valve interstitial cells through the Notch1/Twist1 pathway.
Sun C, Liu H, Si K, Wu Y, Zhao K, Xu R, Zhou Z, Zheng Z. | 11/2/2019 |
| these are the first described de novo missense variants in MEIS2, expanding the known mutation spectrum of the newly recognized human disorder caused by aberrations in this gene. | De novo missense variants in MEIS2 recapitulate the microdeletion phenotype of cardiac and palate abnormalities, developmental delay, intellectual disability and dysmorphic features.
Douglas G, Cho MT, Telegrafi A, Winter S, Carmichael J, Zackai EH, Deardorff MA, Harr M, Williams L, Psychogios A, Erwin AL, Grebe T, Retterer K, Juusola J. | 09/14/2019 |
| Moderate elevation of MEIS2A expression reduced proliferation of MYCN-amplified human neuroblastoma cells, induced neuronal differentiation and impaired the ability of these cells to form tumors in mice | Tumorigenic and Antiproliferative Properties of the TALE-Transcription Factors MEIS2D and MEIS2A in Neuroblastoma.
Groß A, Schulz C, Kolb J, Koster J, Wehner S, Czaplinski S, Khilan A, Rohrer H, Harter PN, Klingebiel T, Langer JD, Geerts D, Schulte D. | 07/6/2019 |
| Loss-of-function MEIS2 mutations were identified in nine patients with palatal defects, congenital heart defects, and intellectual disability. | Heterozygous loss-of-function variants of MEIS2 cause a triad of palatal defects, congenital heart defects, and intellectual disability.
Verheije R, Kupchik GS, Isidor B, Kroes HY, Lynch SA, Hawkes L, Hempel M, Gelb BD, Ghoumid J, D'Amours G, Chandler K, Dubourg C, Loddo S, Tümer Z, Shaw-Smith C, Nizon M, Shevell M, Van Hoof E, Anyane-Yeboa K, Cerbone G, Clayton-Smith J, Cogné B, Corre P, Corveleyn A, De Borre M, Hjortshøj TD, Fradin M, Gewillig M, Goldmuntz E, Hens G, Lemyre E, Journel H, Kini U, Kortüm F, Le Caignec C, Novelli A, Odent S, Petit F, Revah-Politi A, Stong N, Strom TM, van Binsbergen E, DDD study, Devriendt K, Breckpot J., Free PMC Article | 05/11/2019 |
| TAL1 acts as a downstream gene mediating the function of MEIS2 during early hematopoiesis. | MEIS2 regulates endothelial to hematopoietic transition of human embryonic stem cells by targeting TAL1.
Wang M, Wang H, Wen Y, Chen X, Liu X, Gao J, Su P, Xu Y, Zhou W, Shi L, Zhou J., Free PMC Article | 04/20/2019 |
| Mechanistic analyses integrate this unrecognized anti-atrial function of ISL1 with known and newly identified atrial inducers. In this revised view, ISL1 is antagonized by retinoic acid signaling via a novel player, MEIS2. | Revised roles of ISL1 in a hES cell-based model of human heart chamber specification.
Quaranta R, Fell J, Rühle F, Rao J, Piccini I, Araúzo-Bravo MJ, Verkerk AO, Stoll M, Greber B., Free PMC Article | 08/25/2018 |
| High expression of MEIS2 impairs repressive DNA binding of AML1-ETO, inducing increased expression of genes such as the druggable proto-oncogene YES1. | MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML.
Vegi NM, Klappacher J, Oswald F, Mulaw MA, Mandoli A, Thiel VN, Bamezai S, Feder K, Martens JHA, Rawat VPS, Mandal T, Quintanilla-Martinez L, Spiekermann K, Hiddemann W, Döhner K, Döhner H, Stunnenberg HG, Feuring-Buske M, Buske C. | 12/2/2017 |
| we have identified a novel nonsense MEIS2 mutation in a female patient with cleft palate, cardiac septal defect, severe ID, developmental delay and feeding difficulty with gastro-esophageal reflux. Our findings strongly suggest neurocristopathy be included in the clinical features associated with MEIS2 alterations. | De novo MEIS2 mutation causes syndromic developmental delay with persistent gastro-esophageal reflux.
Fujita A, Isidor B, Piloquet H, Corre P, Okamoto N, Nakashima M, Tsurusaki Y, Saitsu H, Miyake N, Matsumoto N. | 04/8/2017 |